Estimated number of deaths from oral cancer attributable to ST use in the US, Sweden, and India
| Study | OR (95% CI) | PAR (95% CI) | No (95% CI) of deaths attributable to ST use |
|---|---|---|---|
| OR=odds ratio; PAR=population attributable risk. | |||
| Estimated prevalence of ST use in US: 3.8% in 1995, 0.6% in women98; annual deaths from oral cavity cancers 2765 in men, 1618 in women.99 Estimated prevalence of ST use in Sweden: 20% of men, 2% of women7,100; annual deaths from oral cavity cancers 88 in men, 65 in women.101 Estimated prevalence of ST use in India: 22% in men and women102; annual deaths from oral cavity cancers 29 054 in men, 17 222 in women.99 | |||
| US | |||
| Mashberg et al45 (ID8) | 0.8 (0.4 to 1.9) | 0 (0 to 0.5) | 0 (0 to 145) |
| Stockwell and Lyman46 (ID10) | 11.2 (4.1 to 30.7) | 28% (10.5 to 53) | 1224 (461 to 2324) |
| Winn et al47 (ID13) | 4.2 (2.6 to 6.7) | 1.9% (0.9 to 3.3) | 30 (15 to 54) |
| Sweden | |||
| Lewin et al48 (ID19) (men only) | 3.3 (0.8 to 12.0) | 32% (0 to 69) | 28 (0 to 61) |
| Schildt et al49 (ID20) (men only) | 0.7 (0.4 to 1.1) | 0 (0 to 2) | 0 (0 to 2) |
| India | |||
| Diskshit and Kanhere52 (ID24) | 5.8 (3.6 to 9.5) | 51% (36 to 65) | 23768 (16838 to 30152) |
| Rao et al54 (ID26) | 2.6 (2.0 to 3.4) | 27% (19 to 34) | 12270 (8818 to 15903) |
| Sankaranarayan et al12 (ID28) | 6.9 (2.8 to 16.8) | 56% (28 to 78) | 26138 (13283 to 35942) |